Literature DB >> 21790236

Pentoxifylline therapy in the management of oral submucous fibrosis.

Ravi Mehrotra1, H P Singh, S C Gupta, M Singh, S Jain.   

Abstract

OBJECTIVES: Oral submucous fibrosis is a common premalignant condition in the Indian subcontinent and is caused by chewing areca nut and other irritants in various forms. Its medical treatment is not yet fully standardized. In this study we compared the efficacy of Pentoxifylline as compared to placebo.
MATERIALS AND METHODS: 75 patients suffering from oral submucous fibrosis were randomly divided into two groups A and B. Group A patients received placebo, while Group B patients received 400 mg. Pentoxifylline for a period of 7 months. Treatment outcome was evaluated on the basis of improvement in symptom and sign scores. Student's t test was applied for comparing the results.
RESULTS: The improvement in total (i.e. symptoms + sign) score was 25% in group A and 49.15% in group B. This difference was found to be statistically significant. (p < 0.05)
CONCLUSION: Treatment regimen of group B was more effective. No significant side effects were seen. A follow up study is required to assess long term outcome of this therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21790236

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  11 in total

1.  Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial.

Authors:  Namdeo Prabhu; Sanjay S Rao; S M Kotrashetti; Shridhar D Baliga; Seema R Hallikerimath; Punnya V Angadi; Rakhi Issrani
Journal:  J Maxillofac Oral Surg       Date:  2013-09-13

Review 2.  Dentoalveolar surgery in oral submucous fibrosis: need for caution.

Authors:  Arvind Ramanathan; Mohan Baliga; Rammohan Kumar
Journal:  J Maxillofac Oral Surg       Date:  2012-08-26

3.  Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis.

Authors:  Chetan J Bhadage; Hemant R Umarji; Karan Shah; Hannamari Välimaa
Journal:  Clin Oral Investig       Date:  2012-08-15       Impact factor: 3.573

Review 4.  Precancerous lesions of oral mucosa.

Authors:  Gurkan Yardimci; Zekayi Kutlubay; Burhan Engin; Yalcin Tuzun
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

5.  Medicinal management of oral submucous fibrosis in the past decade- A systematic review.

Authors:  Chandramani B More; Deepa Jatti Patil; Naman R Rao
Journal:  J Oral Biol Craniofac Res       Date:  2020-08-19

Review 6.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

7.  Pentoxifylline and its applications in dermatology.

Authors:  Iffat Hassan; Konchok Dorjay; Parvaiz Anwar
Journal:  Indian Dermatol Online J       Date:  2014-10

8.  Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis - An Ultrasonographic Study.

Authors:  Jayachandran Sadaksharam; Sureshkumar Mahalingam
Journal:  Contemp Clin Dent       Date:  2017 Apr-Jun

9.  An immunohistochemical study of p53 expressions in oral submucous fibrosis.

Authors:  Sandesh Manjunath; C Girish Himadal; Darshan Devang Divakar; Shaista Haleem; Hussain Ahmed Mohammad Faqeeh; Mohammed Yahya M Alshadidi
Journal:  J Oral Maxillofac Pathol       Date:  2019 May-Aug

Review 10.  Oral submucous fibrosis: an update.

Authors:  Uwe Wollina; Shyam B Verma; Fareedi Mukram Ali; Kishor Patil
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.